Drug Profile
Research programme: retinal disease therapeutics - Fovea Pharmaceuticals/Sanofi
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Fovea Pharmaceuticals; Genzyme Corporation
- Developer Fovea Pharmaceuticals; Sanofi
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinal disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Retinal-disorders in France
- 04 Nov 2017 No recent reports of development identified for research development in Retinal-disorders in USA
- 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis